Stock Events

Esperion Therapeutics 

$2.4
49
+$0+0% Friday 17:31

Statistics

Day High
2.45
Day Low
2.4
52W High
3.32
52W Low
0.71
Volume
21,171
Avg. Volume
26,659
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

7MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.92
-0.5
-0.08
0.34
Expected EPS
0.05
Actual EPS
0.34

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0IIM.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap177.47B
Amgen produces Repatha, a PCSK9 inhibitor that competes directly with Esperion's cholesterol-lowering drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap118.74B
Regeneron Pharmaceuticals, in collaboration with Sanofi, markets Praluent, another PCSK9 inhibitor, directly competing in the cholesterol management market.
Sanofi
SNY
Mkt Cap130B
Sanofi, partnering with Regeneron, is involved in the marketing of Praluent, making it a direct competitor in the cholesterol-lowering space.
Merck &
MRK
Mkt Cap323.59B
Merck & Co. offers cholesterol management drugs that, while not PCSK9 inhibitors, still compete in the broader market for cholesterol treatment solutions.
Astrazeneca
AZN
Mkt Cap245.69B
AstraZeneca provides Crestor, a statin, which is part of the broader cholesterol management market, competing for similar patient populations.
Pfizer
PFE
Mkt Cap163.88B
Pfizer is known for its Lipitor, one of the best-selling cholesterol-lowering drugs, competing in the same therapeutic area.
Novartis
NVS
Mkt Cap244.62B
Novartis has a portfolio of cardiovascular drugs that, while not directly competing as PCSK9 inhibitors, still vie for market share in the broader cardiovascular treatment space.
Abbvie
ABBV
Mkt Cap300.69B
AbbVie, through its acquisition of Allergan, has expanded its portfolio into cardiovascular diseases, indirectly competing with Esperion.
GSK
GSK
Mkt Cap81.16B
GlaxoSmithKline offers a range of cardiovascular drugs, competing in the broader market for heart disease treatments.
Lilly(Eli) &
LLY
Mkt Cap901.36B
Eli Lilly and Company, while not a direct competitor in the PCSK9 space, has a growing interest in cardiovascular diseases, potentially competing for the same patient demographic.

About

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Show more...
CEO
Mr. Sheldon L. Koenig
Employees
218
Country
United States
ISIN
US29664W1053
WKN
000A1W1SJ

Listings